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Atypical familial juvenile hyperuricemic nephropathy associ- Familial juvenile hyperuricemic nephropathy [FJHN
ated with a hepatocyte nuclear factor-1 gene mutation. (MIM 162000)] is an autosomal-dominant condition as-
Background. Familial juvenile hyperuricemic nephropathy sociated with hyperuricemia, gout, and renal disease first(FJHN) is a dominantly inherited condition characterized by
described by Duncan and Dixon in 1960 [1]. FJHN affectsyoung-onset hyperuricemia, gout, and renal disease. The etio-
young men, women, and children equally. Clinical goutlogic genes are unknown, although a locus on chromosome 16
has been identified in some kindreds. Mutations in the gene is a variable feature [2–4], but hypertension and obesity
encoding hepatocyte nuclear factor (HNF)-1 have been associ- are not characteristics of FJHN [2, 4, 5]. Renal impairment
ated with dominant inheritance of a variety of disorders of renal usually develops between 15 to 30 years of age with pro-development, particularly renal cystic disease and early onset
gression to end-stage renal failure (ESRF) within 10 todiabetes; hyperuricemia has been reported in some kindreds.
15 years [4, 6]. Renal ultrasound appearances have beenMethods. To assess a possible role for the HNF-1 gene in
some FJHN kindreds we sequenced the HNF-1 gene in sub- reported showing reduced renal size with abnormal echo-
jects from three unrelated FJHN families with atypical features genicity and occasionally renal cysts in some kindreds [7–9].
of renal cysts or abnormalities of renal development. We also Examination of renal histology typically shows chroniccompared serum urate levels in subjects with HNF-1mutations
tubulointerstitial inflammation with thickening and split-with populations of controls, type 2 diabetic subjects, and sub-
ting of the tubular basement membranes. There is rarelyjects with mild chronic renal failure without HNF-1 mutations.
Results. A splice-site mutation in intron 2, designated evidence of urate crystal deposition [4, 6, 8, 10, 11].
IVS21GT, showed complete co-segregation with FJHN in Allopurinol may ameliorate the progression of the renal
one family with diabetes. Serum urate levels were significantly damage which makes presymptomatic diagnosis of thehigher in the HNF-1 subjects compared with the normal con-
condition important, particularly in children [3, 12, 13].trol subjects (384 mol/L vs. 264 mol/L, P  0.002) and the
There are two biochemical hallmarks of FJHN. Thetype 2 diabetic subjects (397 mol/L vs. 271 mol/L, P 0.01).
Comparison of serum urate levels in the HNF-1 subjects with first is hyperuricemia disproportionate to the degree of
gender-matched subjects with renal impairment of other causes renal dysfunction [2]. The second is a low urate clearance
did not reach significance (402 mol/L vs. 352 mol/L, P 0.2). relative to creatinine, the fractional excretion of uric acidConclusion. Hyperuricemia and young-onset gout are con-
(FEur), of 5.1%  1.6% in men, women, and childrensistent features of the phenotype associated with HNF-1 mu-
[5, 14]. The hyperuricemia that results from the reducedtations, but the mechanism is uncertain. Families with HNF-1
mutations may fit diagnostic criteria for FJHN. Identification of FEur may precede the onset of renal disease [1, 5, 13].
HNF-1 patients by recognizing the features of diabetes and The hypoexcretion of urate suggests that a defect in the
disorders of renal development is important in resolving the transport of urate in the proximal renal tubule is ofgenetic heterogeneity in FJHN.
primary importance in the pathogenesis of this condition
[5, 13, 15, 16]. Urate is freely filtered and approximately
90% is reabsorbed in the proximal tubule. There is bidi-Key words: transcription factors, HNF-1 mutation, hyperuricemia,
familial renal disease, juvenile gout. rectional transport within the proximal tubule involving
presecretory reabsorption, secretion and postsecretoryReceived for publication May 30, 2002
reabsorption [4]. Two mechanisms exist for urate trans-and in revised form September 25, 2002, and November 20, 2002
Accepted for publication December 13, 2002 port within the kidney, a voltage-sensitive urate trans-
porter and a urate/anion exchanger [17, 18]. The rat 2003 by the International Society of Nephrology
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urate/anion transporter (rUAT) has been described in
the rat [19, 20]. Human galectin 9 (hUAT) is homologous
to the rUAT and it functions as a highly selective urate
channel when inserted in lipid bilayers [21, 22]. The
hUAT gene is 96% homologous to a novel gene hUAT2,
which is also likely to be a urate transporter [22]. The
URAT1 urate transporter encoded by SLC22A12 has
recently been described in human kidney [23].
No gene has been identified in the etiology of FJHN.
Linkage analysis has identified a locus for FJHN on chro-
mosome 16p12 in one Japanese kindred and 16p11.2 in
two Czech families [9, 24]. Twelve other United King-
dom kindreds and a third Czech family failed to demon-
strate linkage to this region, which supports a hypothesis
of genetic heterogeneity within FJHN [9, 25]. The region
identified on chromosome 16p11.2 is close to one locus
for autosomal-dominant medullary cystic disease, MCKD2
on chromosome 16p12 (MIM 603860) [26]. It has been
proposed that FJHN and MCKD2 may be two phenotypes
arising from mutations in the same gene [11]. The hUAT
and hUAT2 genes have been mapped to between 17p11.2
and 17p12 on the short arm of chromosome 17 and the
SLC22A12 gene to chromosome 11q13 and all these
genes may be further candidate genes for FJHN, although
they are not within known areas of linkage [22, 23].
Hepatocyte nuclear factor (HNF)-1 mutations have
been described in 12 kindreds and typically cause the
Fig. 1. Pedigrees of kindreds studied. Roman numerals on left of figurerenal cysts and diabetes (RCAD) syndrome [27, 28].
indicate generation number, and the numbers below the symbols indi-
HNF-1 expression has been demonstrated in fetal hu- cate individuals within that generation. The HNF-1 genotype of each
individual tested is indicated below the symbol: N, normal; M, mutatedman metanephric kidney [28]. A wide variety of develop-
allele; FJHN, blackened upper right quadrant; diabetes, blackenedmental renal disorders have been described in association
lower right quadrant; renal cysts/disorder of renal development, black-
with HNF-1 mutations, including hypoplastic glomeru- ened lower left quadrant. The proband in each kindred is marked with
locystic kidney disease, cystic renal dysplasia, solitary an arrow.
functioning kidney, and oligomeganephronia [27, 29–31].
Consistent with a developmental abnormality renal ab-
normalities have been detected in a number of subjects
and DUK595) who form part of the FJHN collection ofin utero on antenatal ultrasound scanning [28–30]. Renal
approximately 60 families held by the Guy’s Hospitalfunction in affected subjects ranges from normal to the
Purine Research Unit. These were atypical FJHN fami-development of ESRF in adolescence or young adult-
lies with a history of renal cystic disease or evidence ofhood [30].
abnormalities of renal development detected on ultra-Hyperuricemia has been reported in subjects with
sound examination. One family also had a history ofHNF-1 mutations [32, 33]. In addition, three young
diabetes developing within the last 5 years (Fig. 1). Thewomen from separate families with different mutations
probands in these families were screened for HNF-1within the UK HNF-1 collection have had gout (Coralie
gene mutations using direct sequencing (see below).Bingham, unpublished data). Since renal cysts have been
When an HNF-1 mutation was found in the proband,reported in a few FJHN families, along with impaired
genetic testing was performed in all consenting familyrenal function, hyperuricemia, and gout, we hypothe-
members and their clinical data were reviewed. Thesized that HNF-1 mutations might be associated with
study was approved by the local Ethics Committee andFJHN and that hyperuricemia may be a consistent fea-
informed consent was obtained from each subject.ture of HNF-1 mutations
Clinical studies
METHODS To assess if hyperuricemia was a generalized feature
Subjects of subjects with HNF-1 mutations, we measured serum
urate levels in nine adult subjects with HNF-1 muta-The study population for genetic analysis consisted of
members of three unrelated families (DUK504, DUK594, tions from five families. Clinical details of five of these
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subjects, but not their urate levels, have been published in the kindred (Fig.1). DNA was not available for testing
from one deceased affected member of the kindred. To[27, 29, 30]. Serum urate levels were compared with
control groups with type 2 diabetes, non-HNF-1 renal test evidence of linkage between FJHN and the mutation
in the HNF-1 gene a logarithm of odds (LOD) scoredisease, and normal subjects. The subjects with type 2
diabetes and the normal controls were gender- and body was computed assuming an autosomal-dominant mode
of inheritance with full penetrance and a gene frequencymass index (BMI)-matched to the subjects with HNF-1
mutations. The subjects with non-HNF-1 renal disease of 0.0001 using Gene Hunter version 2 [35]. This gave
a LOD score of 2.4, which was the maximum LOD scorewere selected from general nephrology clinics. These
subjects had a serum creatinine of 200 mol/L and available with this family. The mutation was not present
in 100 normal chromosomes analyzed by sequencing. Nowere gender-matched to eight of the HNF-1 subjects
who had a serum creatinine of 200 mol/L. Renal mutation in the HNF-1 gene was found in the two other
United Kingdom families with FJHN.subjects were excluded if they gave a history of gout, or
were on allopurinol. Statistical analysis was performed
Clinical characteristicsusing unpaired Student t tests unless stated otherwise.
To study the excretion of uric acid the fractional excre- The clinical characteristics of family DUK504 are
shown in Table 1. Seven of the affected subjects havetion (FEur) was calculated from the uric acid clearance
factored by the creatinine clearance 100. The FEur was hyperuricemia, five have reduced FEur, and three subjects
have young-onset gout. This kindred also includes af-measured in the eight subjects with HNF-1 mutations
who all had a serum creatinine of 200 mol/L and in fected members with renal cysts (N  3) and diabetes
(N  4). Antenatal ultrasound scanning of the probandthe three adult subjects from family DUK504 who were
mutation carriers but were not in ESRF. (subject III2) was suggestive of bilateral pelviureteric
junction obstruction. At the age of 7 months, an intrave-
Mutation analysis of the HNF-1 gene nous urogram confirmed that the left renal pelvis was
distended with a pelviureteric junction obstruction, butThe entire promoter and coding regions of the 9 exons
and the intron-exon boundaries of the HNF-1 gene that the right kidney was normal. He subsequently un-
derwent a left pyeloplasty at the age of 2 years. A renalwere amplified by polymerase chain reaction (PCR) using
genomic DNA from a single proband and sequence spe- ultrasound scan at the age of 13 years showed that the
left kidney was small and the right kidney was enlarged,cific primers [34]. PCR was performed in a 25 L volume
containing 10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl, containing three cysts and one to two echogenic foci
suggestive of calculi. Subject I2 died at the age of 591 to 1.5 mmol/L MgCl2, 200 mol/L desoxynucleoside
triphosphate (dNTP), 2.5 pmol each primer, 0.25 U Am- years in ESRF. She had previously required a pyelo-
plasty. Subject II2 was found to have renal calculi, heplitaq Gold Taq polymerase (Applied Biosystems, War-
rington, UK), and 100 ng DNA. The cycling conditions developed ESRF, and received a renal transplant. He
has since died. Subject II4 had a renal biopsy performedwere 15 minutes at 95	C followed by 35 cycles consisting
of 1 minute at 94	C, 1 minute at 60	C, 2 minutes at 72	C. at the age of 23 years. A generalized mild dilatation was
noted of the proximal tubules with occasional tubulesPCR products were purified using a QIAquick column
(Qiagen, Crawley, UK) and both strands sequenced us- showing large cystic change. The appearances were mild
and nonspecific other than elastosis of the blood vessels.ing a BigDye (version 2) Terminator Cycle Sequencing
kit (Applied Biosystems) according to the manufactur-
Clinical studieser’s recommendations. Reactions were analyzed on an
ABI PrismTM 377 DNA Sequencer (Applied Biosystems). The results are given as means  standard deviation.
The mean serum urate level was 384 ( 128) mol/L inSequencing data were analyzed using FACTURATM and
Sequence Navigator 1.0.1. software. a group of United Kingdom adult subjects with HNF-
1mutations (N 9) compared with 264 ( 54) mol/L
(P  0.002) in a gender- and BMI-matched normal con-
RESULTS
trol population (N  18). The HNF-1 subjects differed
Identification of a mutation in the HNF-1 gene from the controls by having renal impairment (mean
serum creatinine 176  149 mol/L vs. 68  11 mol/L)A novel heterozygous mutation in the HNF-1 gene
was identified in family DUK504. The mutation is at and more diabetes (66.7% vs. 0%, P  0.001 Fisher’s
exact test). Further controls were selected to assess ifthe conserved splice donor site of intron 2, designated
IVS21GT. The mutation is predicted to lead to a renal impairment or diabetes accounted for the hyperuri-
cemia observed. When the diabetic HNF-1 mutationsplicing defect with either exon skipping or intron reten-
tion, potentially resulting in premature termination if a carriers (N 6) were compared with a gender- and BMI-
matched population of type 2 diabetic subjects (N 24),frameshift is introduced. The mutation co-segregated
with FJHN being present in seven of the affected subjects the mean serum urate remained elevated 397 ( 140)
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Table 2. Fractional excretion of uric acid in 11 adult HNF-1 subjects
Family Mutation Gender FEur% Mean FEur%
DUK504 IVS21GT Male 6.3 5.01.3
DUK504 IVS21GT Male 5.8
DUK350 IVS2nt3insT Male 4.2
DUK298a P159fsdelT Male 3.5
DUK504 IVS21GT Female 6.8 8.54.1
DUK350 IVS2nt3insT Female 5.6
DUK350 IVS2nt3insT Female 7.1
DUK350 IVS2nt3insT Female 4.6
DUK507a Q243fsdelC Female 13.5
DUK448a S151P Female 15.3
DUK250a P328L329fsdelCCTCT Female 6.7
a References 27, 29, and 30
Mean values given standard deviation. FEur reference range, 4.9% to 11.3%
(male); 9.9%–15.7% (female).
mol/L vs. 271 ( 94) mol/L (P  0.01). When the
eight HNF-1 subjects with a creatinine 200 mol/L
(mean 127 36 mol/L) were compared with 32 gender-
matched subjects with renal impairment not due to HNF-
1mutations (mean serum creatinine 117 45 mol/L),
the mean serum urate was 402 ( 125) mol/L vs. 352
( 93) mol/L (P  0.2). The FEur results for 11 adult
HNF-1 subjects are shown in Table 2. The mean FEur
in the male subjects was 5.0% ( 1.3%), which is at the
lower limit of the reference range (4.9% to 11.3%). The
mean FEur in the female subjects was reduced at 8.5%
( 4.1%) with a reference range of 9.9% to 15.7%.
DISCUSSION
Family DUK504 has previously been reported as hav-
ing FJHN [2, 5]; it fulfills the diagnostic criteria with
hyperuricemia, reduced FEur, evidence of renal damage,
and three members of the kindred with young-onset gout
[2, 5]. Other conditions causing hyperuricemia, including
enzymatic defects, hemolytic anemia or the use of drugs
that interfere with urate metabolism, have been excluded
[2]. Subjects III2, III4, and III5 were all diagnosed with
FJHN in early childhood, following screening because
of FJHN in a parent. Importantly, their renal function
has improved with allopurinol treatment [12, 13]. This
kindred also includes affected members with renal cysts
and diabetes, the cardinal features of the RCAD syn-
drome associated with HNF-1mutations [27, 28]. Fami-
lies with HNF-1 mutations may therefore fit diagnostic
criteria for FJHN in addition to having diabetes and
disorders of renal development.
Hyperuricemia has previously been reported in sub-
jects from two Japanese families with HNF-1mutations
[32, 33]. Upon reexamination of the other nine HNF-1
families in the United Kingdom collection, we found
evidence of gout in young females (40 years) in three
kindreds (Coralie Bingham, unpublished data). Clinical
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gout is rare in young women as postpuberty women have a
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higher FEur (12.8% 2.9%) compared with men (8.1% teric bud in the developing human embryo and this has
been shown to be a site of HNF-1 expression [28]. A3.2%), which results in lower serum urate levels in
women [14]. This suggested that gout and hyperuricemia report of renal histology is only available from one subject
and the original histology was not available for review.are a general feature of HNF-1 mutations.
Serum urate levels were significantly higher in a group The IVS21GT mutation we report herein occurs
at the conserved splice donor site of intron 2. A differentof United Kingdom adult subjects with HNF-1 muta-
tions compared with a gender- and BMI-matched normal mutation at this site, IVS2nt1GA, has been reported
in a Japanese kindred where three affected memberscontrol population. As 67% of the HNF-1 subjects had
diabetes, which may be associated with hyperuricemia have renal cysts and diabetes and one subject has hyper-
uricemia [33]. These mutations are highly likely to beas part of the insulin resistance syndrome, we also com-
pared the HNF-1 patients with a gender- and BMI- pathogenic and result in aberrant splicing. In order to
make further predictions about the functional effectsmatched population of type 2 diabetic patients. Serum
urate levels were significantly higher in the HNF-1 group. of these splice-site mutations, it would be necessary to
perform studies on mRNA. The major sites of expressionThis would suggest that the hyperuricemia in the diabetic
HNF-1 group of subjects is not just secondary to diabetes in the kidney, liver, pancreas, gut, and lung are not
readily available for sampling from patients making fur-and insulin resistance. Comparison of a gender-matched
population of subjects with renal impairment not due to ther study difficult.
Our results suggest that all HNF-1 mutations causeHNF-1 mutations showed that the urate level was
higher in the HNF-1 patients compared with the non- hyperuricemia. The mechanism is unknown but may be
a result of altered urate transport as well as chronic renalHNF-1 patients, but this difference failed to reach sig-
nificance. The renal impairment in the HNF-1 group impairment. HNF-1 is structurally related to HNF-1
,
which is another member of the homeodomain-con-may therefore be contributing to their hyperuricemia
independent of any direct mutational effect on urate taining superfamily of transcription factors [36]. In situ
hybridization experiments in developing rat kidney havetransport. However, there is evidence from the FEur to
support a possible direct mutational effect on urate trans- shown that both HNF-1 and HNF-1
 are expressed in
the renal proximal tubule. HNF-1 is expressed fromport. In chronic renal failure, the FEur increases as the
glomerular filtration rate falls and there is a nonlinear the earliest inductory phases of development, HNF-1

appears later in the postinductory phase in cells commit-increase of plasma urate with a linear increase in plasma
creatinine. Thus, secondary clinical gout is very rare in ted to tubular differentiation [37]. The HNF-1
 knock-
out mouse has evidence of renal proximal tubular dys-patients with chronic renal failure [2, 4]. However, in
our subjects the FEur is reduced (mean 8.5%) below the function with a renal Fanconi syndrome with polyuria
(85% body weight/day), aminoaciduria, phosphaturia,reference range (9.9% to 15.7%) in the female HNF-1
subjects with a serum creatinine 200 mol/L and is and glucosuria [38]. The defect in renal proximal tubular
glucose resorption is caused by a significant reductionclose to the lower limit of the reference range in the
male subjects (mean 5.0%) with a reference range of in expression of the high-capacity/low-affinity sodium-
glucose transporter-2 (SGLT-2) [39]. HNF-1
 probably4.9% to 11.3%, but the number of subjects was small.
Our results support the hypothesis that there is genetic has a role in the regulation of transcription of the SGLT-2
gene mediated through HNF-1
 binding sites. Humanheterogeneity within FJHN as we did not identify a muta-
tion in the HNF-1 gene in two out of the three families subjects with heterozygous HNF-1
 mutations have a
reduced renal threshold for glucose and thus developtested, even though they were selected for phenotypic
features suggestive of HNF-1 mutations. This and the glucosuria. This is likely to result from a direct effect of
reduced HNF-1
 activity leading to reduced transcriptionother regions of linkage outside the HNF-1 region on
17cen-q 21.3 suggest that HNF-1mutations are a minor of the SGLT-2 glucose transporter [39–41]. It is possible
to speculate that a similar mechanism may exist wherebycause of FJHN. We did not test other candidate genes
or regions in these families. The two families without reduced HNF-1 activity reduces transcription of the
human urate transporters URAT1 and hUAT mediatedmutations had affected members with renal cystic disease
or evidence of disordered renal development seen on through HNF-1 binding sites in the SLC22A12 and
hUAT genes. This hypothesis is difficult to test as theultrasound scanning in addition to hyperuricemia, but
they did not have a history of diabetes. Early-onset dia- HNF-1 homozygous knockout mouse dies at 6.5 to 7.0
days postconception without developing visceral or pari-betes or evidence of impaired glucose tolerance has been
a feature in the majority (10/12) of the reported families etal endoderm [42]. Screening of the sequence upstream
of the SLC22A12 gene in human and mouse for HNF-1with HNF-1mutations [30]. It is interesting to note that
two subjects in the DUK504 kindred had pelviureteric binding sites using http://bindgene.ex.ac.uk revealed a
probable HNF-1 binding site. Screening upstream of thejunction obstruction and required renal pyeloplasties.
The pelviureteric junction region derives from the ure- UAT gene found no clear evidence of binding sites.
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in ameliorating the progressive renal disease in familial juvenileCONCLUSION
hyperuricemic nephropathy: A six year update. Adv Exp Med Biol
We have identified a mutation in the HNF-1 gene in 431:7–11, 1998
13. Fairbanks LD, Cameron JS, Venkat-Raman G, et al: Early treat-a single kindred with FJHN. This kindred also includes
ment with allopurinol in familial juvenile hyperuricemic nephropa-affected members with renal cysts and recently diabetes, thy (FJHN) ameliorates progression of renal disease in long-term
the cardinal features of the RCAD syndrome that is studies. Q J Med 95:597–607, 2002
14. Simmonds HA: Purine and pyrimidine disorders, in The Inheritedassociated with HNF-1 mutations. Absence of this mu-
Metabolic Diseases, edited by Holton JB, Edinburgh, Churchilltation in the two other FJHN kindreds screened is further Livingstone, 1994, pp 297–350
evidence for genetic heterogeneity within FJHN. Screen- 15. Lhotta K, Gruber J, Sgonc R, et al: Apoptosis of tubular epithelial
cells in familial juvenile gouty nephropathy. Nephron 79:340–344,ing for HNF-1mutations in FJHN is particularly appro-
1998priate in those kindreds with renal cystic disease or other 16. Marinaki AM, Cameron JS, Simmonds HA: Inherited disorders
abnormalities of renal development, especially where of purine metabolism and transport, in Oxford Textbook of Clinical
Nephrology (third edition), edited by Davidson AM, Cameron JS,there is also a history of diabetes. Hyperuricemia and
Gru¨nfeld JP, et al, Oxford, Oxford University Press, 2002 (inyoung-onset gout affecting both men and women are press)
further features of the variable phenotype associated 17. Roch-Ramel F, Werner D, Guisan B: Urate transport in brush-
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